Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465001 | 0.84 | ADORA2A (0.45) | ADORA2ATMIGD3ADORA1PPARGPPARD | |
| SCHEMBL448404 | 0.82 | PPARG (0.41) | ADORA2ATMIGD3ADORA1PPARGPPARD | |
| SCHEMBL450536 | 0.80 | CDK1 (0.45) | ADORA2AADORA1 | |
| SCHEMBL447288 | 0.79 | ADORA2A (0.49) | ADORA2AADORA1PPARGPPARDCTSL | |
| SCHEMBL448173 | 0.78 | ADORA2A (0.40) | ADORA2ATMIGD3ADORA1PPARGPPARD | |
| SCHEMBL465000 | 0.75 | CDK1 (0.40) | — | |
| SCHEMBL29501915 | 0.72 | ADORA2A (0.53) | ADORA2ATMIGD3ADORA1ADORA2B | |
| SCHEMBL7744345 | 0.71 | PDE8A (0.57) | ADORA2AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL7743666 | 0.67 | ADORA3 (0.69) | ADORA2AADORA1ADORA2B | |
| SCHEMBL448638 | 0.66 | CDC7 (0.37) | ADORA2AADORA1ADORA2BPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825102-B2 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2010-11-02 | — | — | US | claimed |
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | claimed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | claimed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | disclosed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-108367016-B | A3 adenosine receptor ligands for the treatment of ectopic fat accumulation | 坎-菲特生物药物有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2021-03-11 | — | — | US | disclosed |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| US-7825102-B2 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2010-11-02 | — | — | US | disclosed |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2008-12-04 | — | — | US | disclosed |
| EP-1959939-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | Can-Fite Biopharma Ltd. (IL) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007063538-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
| US-20070099865-A1 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | disclosed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099865-A1 | Treatment of dry eye conditions | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885TMIGD3 1645/4885ADORA1 5/4885 |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | ADORA2A 2/4885TMIGD3 1891/4885ADORA1 11/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885TMIGD3 1577/4885ADORA1 3/4885 |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | ADORA3, ADORA2A, IL1RN | ADORA2A 2/4885TMIGD3 3382/4885ADORA1 5/4885 |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885TMIGD3 1769/4885ADORA1 4/4885 |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885TMIGD3 2297/4885ADORA1 3/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885TMIGD3 3422/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.